Repligen Co. (NASDAQ:RGEN) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 58,172 shares of the biotechnology company’s stock after buying an additional 669 shares during the quarter. Russell Investments Group Ltd.’s holdings in Repligen were worth $8,373,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Repligen during the fourth quarter worth about $397,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in Repligen during the 4th quarter worth approximately $55,000. ExodusPoint Capital Management LP increased its stake in Repligen by 122.8% during the 4th quarter. ExodusPoint Capital Management LP now owns 213,718 shares of the biotechnology company’s stock worth $30,763,000 after buying an additional 117,787 shares in the last quarter. Westpac Banking Corp lifted its position in shares of Repligen by 17.9% in the fourth quarter. Westpac Banking Corp now owns 21,725 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 3,305 shares in the last quarter. Finally, Cinctive Capital Management LP boosted its stake in shares of Repligen by 717.1% in the fourth quarter. Cinctive Capital Management LP now owns 61,398 shares of the biotechnology company’s stock worth $8,838,000 after acquiring an additional 53,884 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Up 6.7 %

Shares of NASDAQ RGEN opened at $122.86 on Friday. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm’s 50-day moving average is $143.12 and its two-hundred day moving average is $146.32. The company has a market capitalization of $6.90 billion, a PE ratio of -240.90, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RGEN. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, April 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $178.64.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.